ATTR-01 / Accession Therap - LARVOL DELTA

A phase 1 study of ATTR-01, a novel oncolytic adenovirus targeting αvβ6 integrin, which expresses the anti-PD-L1 antibody payload in tumour following intravenous delivery in patients with selected epithelial tumours (ESMO 2025) - No abstract available

Clinical • Oncolytic virus • P1 data • Oncology • Solid Tumor

ATTEST: A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Accession Therapeutics Limited | Suspended ➔ Recruiting

Enrollment open • Solid Tumor

ATTEST: A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours (clinicaltrials.gov) - P1/2 | N=72 | Suspended | Sponsor: Accession Therapeutics Limited | Recruiting ➔ Suspended

Trial suspension • Solid Tumor

ATTEST: A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours (clinicaltrials.gov) - P1/2 | N=72 | Recruiting | Sponsor: Accession Therapeutics Limited

New P1/2 trial • Solid Tumor